Survodutide (BI 456906) is a synthetic peptide co-agonist at the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R). Developed as a long-acting weekly compound, it is designed to balance glucagon receptor agonism – for energy expenditure and hepatic lipid mobilization – with GLP-1 receptor agonism for insulin secretion augmentation, appetite suppression, and glycemic regulation.
Researchers have studied Survodutide for its complementary dual mechanism targeting two distinct axes of metabolic regulation. Research in preclinical models has examined how GCGR activation increases hepatic glucose output and thermogenesis through UCP-1 induction in brown adipose tissue, while simultaneous GLP-1R activation helps counterbalance potential hyperglycemic effects of GCGR agonism. Studies have explored how this balance can be tuned through the relative receptor activity ratio.
Preclinical and clinical research has examined Survodutide’s effects on obesity-related metabolic parameters, including liver steatosis, dyslipidemia, and body composition. Studies have generated data on its activity in models of metabolic dysfunction-associated steatohepatitis (MASH), exploring how combined GCGR/GLP-1R agonism affects hepatic inflammation and fibrosis markers. Its dual mechanism makes it a useful research tool for studying the interplay between glucagon and incretin biology in the liver.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
